In the present study, the higher percentage of patients with T2DM as a complication (44.5% for ARBs and 37.5% for CCBs), the higher mean UACR (159.7 mg/g Cr for ARB and 86.9 mg/gCr for CCB), and the higher mean NT-proBNP (161.5 pg/mL for ARB and 74.1 pg/mL for CCB) in the ARB subgroup than the CCB subgroup among patients treated with esaxerenone suggests that the ARB subgroup may have included more patients with diabetic kidney disease. This evidence concerns the gene NPPB and diabetic kidney disease.